Inotek Vision for Glaucoma Supported by $21M in Financing
By Catherine Shaffer
Friday, September 27, 2013
Inotek Pharmaceuticals Corp., of Lexington, Mass., plans to apply $21 million in proceeds from a venture financing, including $7 million in venture debt financing, to advance its A1 subtype adenosine mimetic for glaucoma and ocular hypertension.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.